# The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

> **NCT02174250** · PHASE1 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Istradefylline 40 mg
- **DRUG:** Rifampin 300mg BID + istradefylline 40mg Day 8 only

## Key facts

- **NCT ID:** NCT02174250
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-08
- **Final completion:** 2014-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174250, "The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02174250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*